Lupin growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+23.1%+13.5%+20.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+66.9%+38.7%+111.9%
+80.9%+57.4%+184.9%
+62.0%+70.8%+332.3%
+62.3%+71.1%+344.5%
+31.4%+21.7%+4.5%
+30.2%+20.3%+14.6%
+1,655.0%−87.7%+80.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

LUPIN₹1,989.90

Lupin Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹90,978 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+20.2+13.5+23.1—
EBITDA Growth—+111.9+38.7+66.9—
EBIT Growth—+184.9+57.4+80.9—
Net Income Growth—+332.3+70.8+62.0—
EPS Growth—+344.5+71.1+62.3—
Total Assets Growth—+4.5+21.7+31.4—
Total Equity Growth—+14.6+20.3+30.2—
Cash from Operations Growth—+80.5-87.7+1,655.0—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.